Sea Changes In Regulation And The Market: Top Stories Of 2008
This article was originally published in The Tan Sheet
Executive Summary
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
You may also be interested in...
P&G Focuses On Consumer Health, “Deemphasizes” Pharma
Procter & Gamble says consumer health trends are on its side as the company increases focus on its consumer health business and moves away from pharmaceuticals
P&G Says Zegerid Switch Proposal Should Drop “Immediate Release” Claim
The proton pump inhibitor Zegerid should not be allowed on the over-the-counter market with the label claim "immediate release," says Prilosec OTC marketer Procter & Gamble
The JUPITER Results: Will The Planets Align For OTC Statins?
AstraZeneca's JUPITER trial onCrestor (rosuvastatin) greatly expands the pool of patients who may benefit from statin use, which could help make the case for an OTC switch in the cholesterol-lowering class in the future